2019 Financials

Dear Friends,

In light of the COVID-19 situation, we have made the conscious decision to forego an Annual Report publication for 2019. Our obligation is to keep critical Parkinson’s research moving forward with as little disruption as possible. Therefore, we have pivoted our staff time to be flexible and responsive to scientists’ needs, and support the 6 million people worldwide living with Parkinson’s disease — including the sixty thousand who will be diagnosed this year —through this challenging time. Additionally, we were able to reallocate any production savings back to research projects.

Current copies of our audited 2019 financials for the United States and Canada are available on this page. 

2019 marked a year of momentous progress in neuroscience — and Parkinson’s disease research specifically. Novel discoveries expanded rapidly alongside unprecedented investment in the later-stage work of pre-clinical and clinical drug development. The pipeline of potential treatments continues to grow and diversify, and the goal of lessening Parkinson’s individual and global burden has never been closer. 

Of course, much work remains to be done and we can’t do it without the dedication and optimism of the Parkinson’s community. We are extremely grateful for your commitment to our mission and we look forward to acknowledging our supporters in next year’s two-year Annual Report. 

With thanks,

Todd Sherer, PhD, Chief Executive Officer
 

Deborah W. Brooks, Co-Founder and Executive Chairman

Read our financial management philosophy statement.